{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1363670319308430720.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1038/hr.2010.221"}},{"identifier":{"@type":"URI","@value":"http://www.nature.com/articles/hr2010221.pdf"}},{"identifier":{"@type":"URI","@value":"http://www.nature.com/articles/hr2010221"}},{"identifier":{"@type":"PMID","@value":"21124330"}}],"dc:title":[{"@value":"Benidipine reduces albuminuria and plasma aldosterone in mild-to-moderate stage chronic kidney disease with albuminuria"}],"description":[{"notation":[{"@value":"Benidipine inhibits both L- and T-type Ca channels, and has been shown to dilate the efferent arterioles as effectively as the afferent arterioles. In this study, we conducted an open-label and randomized trial to compare the effects of benidipine with those of amlodipine on blood pressure (BP), albuminuria and aldosterone concentration in hypertensive patients with mild-to-moderate stage chronic kidney disease (CKD). Patients with BP ≥ 130/80 mm Hg, with estimated glomerular filtration rate (eGFR) of 30-90 ml min(-1) per 1.73 m(2), and with albuminuria30 mg per g creatinine (Cr), despite treatment with the maximum recommended dose of angiotensin II receptor blockers (ARBs) were randomly assigned to two groups. Patients received either of the following two treatment regimens: 2 mg per day benidipine, which was increased up to a dose of 8 mg per day (n=52), or 2.5 mg per day amlodipine, which was increased up to a dose of 10  mg per day (n=52). After 6 months of treatment, a significant and comparable reduction in the systolic and diastolic BP was observed in both groups. The decrease in the urinary albumin to Cr ratio in the benidipine group was significantly lower than that in the amlodipine group. Although plasma renin activity was not different in the two groups, plasma aldosterone levels were significantly decreased in the benidipine group. Moreover, urinary Na/K ratio was significantly decreased in the benidipine group but remained unchanged in the serum. It may be concluded that benidipine results in a greater reduction of plasma aldosterone and albuminuria than amlodipine, and that these effects are independent of BP reduction."}]}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1383670319308430724","@type":"Researcher","foaf:name":[{"@value":"Masanori Abe"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670319308430722","@type":"Researcher","foaf:name":[{"@value":"Kazuyoshi Okada"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670319308430720","@type":"Researcher","foaf:name":[{"@value":"Noriaki Maruyama"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670319308430721","@type":"Researcher","foaf:name":[{"@value":"Shiro Matsumoto"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670319308430723","@type":"Researcher","foaf:name":[{"@value":"Takashi Maruyama"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670319308430727","@type":"Researcher","foaf:name":[{"@value":"Takayuki Fujita"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670319308430725","@type":"Researcher","foaf:name":[{"@value":"Koichi Matsumoto"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670319308430726","@type":"Researcher","foaf:name":[{"@value":"Masayoshi Soma"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"09169636"},{"@type":"EISSN","@value":"13484214"}],"prism:publicationName":[{"@value":"Hypertension Research"}],"dc:publisher":[{"@value":"Springer Science and Business Media LLC"}],"prism:publicationDate":"2010-12-02","prism:volume":"34","prism:number":"2","prism:startingPage":"268","prism:endingPage":"273"},"reviewed":"false","dcterms:accessRights":"http://purl.org/coar/access_right/c_abf2","dc:rights":["http://www.springer.com/tdm"],"url":[{"@id":"http://www.nature.com/articles/hr2010221.pdf"},{"@id":"http://www.nature.com/articles/hr2010221"}],"createdAt":"2010-12-02","modifiedAt":"2023-05-18","foaf:topic":[{"@id":"https://cir.nii.ac.jp/all?q=Male","dc:title":"Male"},{"@id":"https://cir.nii.ac.jp/all?q=Dihydropyridines","dc:title":"Dihydropyridines"},{"@id":"https://cir.nii.ac.jp/all?q=Blood%20Pressure","dc:title":"Blood Pressure"},{"@id":"https://cir.nii.ac.jp/all?q=Severity%20of%20Illness%20Index","dc:title":"Severity of Illness Index"},{"@id":"https://cir.nii.ac.jp/all?q=Angiotensin%20Receptor%20Antagonists","dc:title":"Angiotensin Receptor Antagonists"},{"@id":"https://cir.nii.ac.jp/all?q=Glomerulonephritis","dc:title":"Glomerulonephritis"},{"@id":"https://cir.nii.ac.jp/all?q=Albuminuria","dc:title":"Albuminuria"},{"@id":"https://cir.nii.ac.jp/all?q=Humans","dc:title":"Humans"},{"@id":"https://cir.nii.ac.jp/all?q=Diabetic%20Nephropathies","dc:title":"Diabetic Nephropathies"},{"@id":"https://cir.nii.ac.jp/all?q=Aldosterone","dc:title":"Aldosterone"},{"@id":"https://cir.nii.ac.jp/all?q=Aged","dc:title":"Aged"},{"@id":"https://cir.nii.ac.jp/all?q=Nephrosclerosis","dc:title":"Nephrosclerosis"},{"@id":"https://cir.nii.ac.jp/all?q=Sodium","dc:title":"Sodium"},{"@id":"https://cir.nii.ac.jp/all?q=Middle%20Aged","dc:title":"Middle Aged"},{"@id":"https://cir.nii.ac.jp/all?q=Calcium%20Channel%20Blockers","dc:title":"Calcium Channel Blockers"},{"@id":"https://cir.nii.ac.jp/all?q=Chronic%20Disease","dc:title":"Chronic Disease"},{"@id":"https://cir.nii.ac.jp/all?q=Hypertension","dc:title":"Hypertension"},{"@id":"https://cir.nii.ac.jp/all?q=Potassium","dc:title":"Potassium"},{"@id":"https://cir.nii.ac.jp/all?q=Female","dc:title":"Female"},{"@id":"https://cir.nii.ac.jp/all?q=Amlodipine","dc:title":"Amlodipine"},{"@id":"https://cir.nii.ac.jp/all?q=Glomerular%20Filtration%20Rate","dc:title":"Glomerular Filtration Rate"}],"relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1050013397240361344","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Calcium channel blocker in patients with chronic kidney disease"}]},{"@id":"https://cir.nii.ac.jp/crid/1360567189445395072","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"L/N-Type Calcium Channel Blocker Cilnidipine Added to  Renin-Angiotensin Inhibition Improves Ambulatory Blood Pressure Profile and Suppresses Cardiac Hypertrophy in Hypertension with Chronic Kidney Disease"}]},{"@id":"https://cir.nii.ac.jp/crid/1360848658336512384","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Effects of calcium channel blocker-based combinations on intra-individual blood pressure variability: post hoc analysis of the COPE trial"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001205106177792","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Effects of Calcium-Channel Blocker Benidipine-Based Combination Therapy on Cardiac Events　― Subanalysis of the COPE Trial ―"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001205226593664","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Effects of the T/L-type Calcium Channel Blocker Benidipine on Albuminuria and Plasma Aldosterone Concentration"}]},{"@id":"https://cir.nii.ac.jp/crid/1390001206434447360","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"ja","@value":"カルシウム拮抗薬"},{"@language":"en","@value":"Calcium Channel Blockers"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282680203722240","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Improvements in Augmentation Index and Urinary Albumin Excretion With Benidipine in Hypertensive Patients With Chronic Kidney Disease"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282763072752256","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"ja","@value":"糖尿病性腎症を克服する"},{"@language":"en","@value":"To Overcome The Diabetic Kidney Disease"},{"@language":"ja-Kana","@value":"トウニョウビョウセイジンショウ オ コクフク スル"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1038/hr.2010.221"},{"@type":"OPENAIRE","@value":"doi_dedup___::4dde43a26eb56aa666cd2fa84816273e"},{"@type":"CROSSREF","@value":"10.4264/numa.77.5_319_references_DOI_IuntSwSVY1PZHB5i1BHD52u6UHx"},{"@type":"CROSSREF","@value":"10.1007/s10157-021-02153-1_references_DOI_IuntSwSVY1PZHB5i1BHD52u6UHx"},{"@type":"CROSSREF","@value":"10.4264/numa.73.12_references_DOI_IuntSwSVY1PZHB5i1BHD52u6UHx"},{"@type":"CROSSREF","@value":"10.1536/ihj.15-208_references_DOI_IuntSwSVY1PZHB5i1BHD52u6UHx"},{"@type":"CROSSREF","@value":"10.3390/ijms140816866_references_DOI_IuntSwSVY1PZHB5i1BHD52u6UHx"},{"@type":"CROSSREF","@value":"10.1536/ihj.14-034_references_DOI_IuntSwSVY1PZHB5i1BHD52u6UHx"},{"@type":"CROSSREF","@value":"10.1038/hr.2015.104_references_DOI_IuntSwSVY1PZHB5i1BHD52u6UHx"},{"@type":"CROSSREF","@value":"10.1253/circj.cj-17-0592_references_DOI_IuntSwSVY1PZHB5i1BHD52u6UHx"}]}